rs36209567
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM1PM2PP5_Very_Strong
The NM_019616.4(F7):c.995C>T(p.Ala332Val) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000401 in 1,612,734 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.00036 ( 0 hom., cov: 33)
Exomes 𝑓: 0.00040 ( 0 hom. )
Consequence
F7
NM_019616.4 missense
NM_019616.4 missense
Scores
1
13
5
Clinical Significance
Conservation
PhyloP100: 7.22
Genes affected
F7 (HGNC:3544): (coagulation factor VII) This gene encodes coagulation factor VII which is a vitamin K-dependent factor essential for hemostasis. This factor circulates in the blood in a zymogen form, and is converted to an active form by either factor IXa, factor Xa, factor XIIa, or thrombin by minor proteolysis. Upon activation of the factor VII, a heavy chain containing a catalytic domain and a light chain containing 2 EGF-like domains are generated, and two chains are held together by a disulfide bond. In the presence of factor III and calcium ions, the activated factor then further activates the coagulation cascade by converting factor IX to factor IXa and/or factor X to factor Xa. Defects in this gene can cause coagulopathy. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing to generate mature polypeptides. [provided by RefSeq, Aug 2015]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PM1
In a chain Factor VII heavy chain (size 253) in uniprot entity FA7_HUMAN there are 72 pathogenic changes around while only 5 benign (94%) in NM_019616.4
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 13-113118668-C-T is Pathogenic according to our data. Variant chr13-113118668-C-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 12076.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr13-113118668-C-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
F7 | NM_019616.4 | c.995C>T | p.Ala332Val | missense_variant | 8/8 | ENST00000346342.8 | NP_062562.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
F7 | ENST00000346342.8 | c.995C>T | p.Ala332Val | missense_variant | 8/8 | 1 | NM_019616.4 | ENSP00000329546.4 | ||
F7 | ENST00000375581.3 | c.1061C>T | p.Ala354Val | missense_variant | 9/9 | 1 | ENSP00000364731.3 | |||
F7 | ENST00000541084.5 | c.809C>T | p.Ala270Val | missense_variant | 6/6 | 2 | ENSP00000442051.2 |
Frequencies
GnomAD3 genomes AF: 0.000362 AC: 55AN: 152064Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
55
AN:
152064
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000563 AC: 140AN: 248594Hom.: 0 AF XY: 0.000547 AC XY: 74AN XY: 135182
GnomAD3 exomes
AF:
AC:
140
AN:
248594
Hom.:
AF XY:
AC XY:
74
AN XY:
135182
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000405 AC: 591AN: 1460554Hom.: 0 Cov.: 33 AF XY: 0.000380 AC XY: 276AN XY: 726586
GnomAD4 exome
AF:
AC:
591
AN:
1460554
Hom.:
Cov.:
33
AF XY:
AC XY:
276
AN XY:
726586
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000361 AC: 55AN: 152180Hom.: 0 Cov.: 33 AF XY: 0.000336 AC XY: 25AN XY: 74404
GnomAD4 genome
AF:
AC:
55
AN:
152180
Hom.:
Cov.:
33
AF XY:
AC XY:
25
AN XY:
74404
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
0
ALSPAC
AF:
AC:
2
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
2
ExAC
AF:
AC:
88
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:15Uncertain:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 30, 2024 | Identified in the homozygous state or with a pathogenic variant on the opposite allele in multiple unrelated patients in the literature (PMID: 15735798, 24533960); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Also known as A294V; This variant is associated with the following publications: (PMID: 24533960, 31064749, 22180436, 7981691, 30431218, 31980526, 31589614, 29431110, 29618153, 33406812, 15735798, 35552711, 36944032, 25582404, 11931672, 18282149, 15456489, 7919338, 10862079) - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 01, 2021 | This sequence change replaces alanine with valine at codon 354 of the F7 protein (p.Ala354Val). The alanine residue is moderately conserved and there is a small physicochemical difference between alanine and valine. This variant is present in population databases (rs36209567, ExAC 0.1%). This missense change has been observed in individuals with factor VII deficiency (PMID: 7919338, 7981691, 10862079, 15735798). It has also been observed to segregate with disease in related individuals. This variant is also known as Ala294Val. ClinVar contains an entry for this variant (Variation ID: 12076). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). For these reasons, this variant has been classified as Pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jan 01, 2023 | F7: PS4, PM2, PS3:Moderate, PP4 - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center | Feb 25, 2021 | PS3, PM3_Supporting, PP3 - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Jul 16, 2024 | PP5, PM3, PS3 - |
Factor VII deficiency Pathogenic:4
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 2000 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Sep 11, 2019 | This variant was classified as: Likely pathogenic. The following ACMG criteria were applied in classifying this variant: PM1,PM2,PP3,PP5. - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Aug 15, 2018 | The F7 c.1061C>T (p.Ala354Val) missense variant, previously known as p.Ala294Val, has been reported in more than seven studies in which it is found in a total of more than 97 alleles in individuals with factor VII deficiency, including 10 homozygotes and four compound heterozygotes (Bernardi et al. 1994; Wulff et al. 2000; Fromovich-Amit et al. 2004; Mariani et al. 2005; Marty et al. 2008; Branchini et al. 2012; Pavlova et al. 2015). Of note, this variant is also described in cis with a second variant, c.11128delC, in an additional 111 alleles in affected individuals, including 26 individuals homozygous for both variants. The p.Ala354Val variant was absent from 20 controls, but is reported at a frequency of 0.00128 in the European (non-Finnish) population of the Exome Aggregation Consortium. Functional analysis of FVII activity in the plasma of a homozygous individual carrying this variant and the second variant, c.11128delC, showed drastically reduced activity. In vivo studies of the p.Ala354Val variant identified decreased activation of FX by variant FVII protein; however, functional studies showed discordant results when evaluating alterations in the variant protein's interaction with activators and cofactors (Toso et al. 2002; Fromovich-Amit et al. 2004; Branchini et al. 2012). Based on the evidence, the p.Ala354Val variant is classified as pathogenic for factor VII deficiency. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Pathogenic, criteria provided, single submitter | research | NIHR Bioresource Rare Diseases, University of Cambridge | Feb 01, 2019 | - - |
Congenital factor VII deficiency Pathogenic:3Uncertain:1
Uncertain significance, flagged submission | clinical testing | Revvity Omics, Revvity | Dec 10, 2020 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | ISTH-SSC Genomics in Thrombosis and Hemostasis, KU Leuven, Center for Molecular and Vascular Biology | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Dec 21, 2023 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with factor VII deficiency (MIM#227500) and myocardial infarction, decreased susceptibility to (MIM#608446). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0115 - Variants in this gene are known to have variable expressivity. Patients with the same genotype have been observed with phenotypes ranging from asymptomatic to symptomatic (PMID: 18976247). (I) 0200 - Variant is predicted to result in a missense amino acid change from alanine to valine. (I) 0252 - This variant is homozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 for a recessive condition (157 heterozygotes, 0 homozygotes). (SP) 0309 - An alternative amino acid change at the same position has been observed in gnomAD (v2) (3 heterozygotes, 0 homozygotes). (I) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools. (I) 0600 - Variant is located in the annotated trypsin domain (DECIPHER). (I) 0705 - No comparable missense variants have previous evidence for pathogenicity. (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been observed in many homozygote individuals, including individuals homozygote for this variant in cis with p.(Pro442Hisfs*32), and in compound heterozygote individuals, with reduced FVII activity. It has also been reported as pathogenic and likely pathogenic in ClinVar; including one VUS classification (PMID: 18976247). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Genetics and Molecular Pathology, SA Pathology | Oct 07, 2022 | The F7 c.995C>T variant is classified as LIKELY PATHOGENIC (PM2_Supporting, PM1, PM3, PP4) The F7 c.995C>T variant is a single nucleotide substitution in exon 8/8 of the F7 gene, which is predicted to change the alanine at position 332 in the protein to valine. This variant is in dbSNP (rs36209567) and is present in population databases at extremely low frequency (0.00002%, AR) (PM2_Supporting). The variant is in a functional domain (PM1). This variant has been reported as homozygous and compound heterozygous and was detected in trans in this patient with a likely pathogenic variant (PM3). The patient’s phenotype is highly specific for a disease with a single genetic aetiology (biochemical functional assay show low FVII activity) (PP4). - |
Congenital factor VII deficiency;C1832662:Myocardial infarction, susceptibility to Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 27, 2022 | - - |
Abnormal bleeding Pathogenic:1
Likely pathogenic, criteria provided, single submitter | research | NIHR Bioresource Rare Diseases, University of Cambridge | Feb 01, 2019 | - - |
F7-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 13, 2024 | The F7 c.1061C>T variant is predicted to result in the amino acid substitution p.Ala354Val. This variant, previously described as p.Ala294Val using legacy nomenclature, has been reported in many patients to be causative for recessive Factor VII Deficiency (see, for example, Wulff et al. 2000. PubMed ID: 10862079; Millar et al. 2000. PubMed ID: 11129332; Mariani et al. 2005. PubMed ID: 15735798; http://F7-db.eahad.org/). This variant is reported in 0.10% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Uncertain
.;.;D
Eigen
Uncertain
Eigen_PC
Benign
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;D;D
M_CAP
Uncertain
D
MetaRNN
Uncertain
T;T;T
MetaSVM
Uncertain
D
MutationAssessor
Benign
.;.;N
PrimateAI
Uncertain
T
PROVEAN
Uncertain
.;D;D
REVEL
Uncertain
Sift
Uncertain
.;D;D
Sift4G
Uncertain
D;D;D
Polyphen
0.98, 0.98
.;D;D
Vest4
MVP
MPC
0.72
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at